---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-044631"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2021-08-16T23:59:59+00:00"
generated_at: "2026-06-29T09:58:27.172380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q2 net loss $14.0M; advances Alzheimer's trials; open label extension initiated

## Summary
- Net loss $14.0M ($0.38/sh) vs $2.0M loss in Q2 2020; R&D expenses $12.0M (up from $1.7M).
- Cash and investments $349.9M as of June 30, 2021, up from $268.2M at year-end 2020.
- Open label extension started for LIFT-AD and ACT-AD trials; topline data ACT-AD by H1 2022, LIFT-AD by end 2022.
- Phase 2 trial of ATH-1017 for Parkinson's disease dementia targeted to start by end 2021; IND for ATH-1020 by end 2021.
- COO Mark Litton assumes day-to-day leadership; board chair Tadataka Yamada died; Kelly Romano appointed chair.

## SEC filing metadata
- accession: 0001564590-21-044631
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2021-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000156459021044631/0001564590-21-044631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000156459021044631/atha-8k_20210816.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-044631
- JSON: https://secwatch.observer/filing/0001564590-21-044631.json
- Plain text: https://secwatch.observer/filing/0001564590-21-044631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.